Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Endometrial carcinomas in 2021: What to say and what to do?]

Annales de pathologie - 1 Mar 2022

Just Pierre-Alexandre, Genestie Catherine

Abstract excerpt

The treatment of endometrial carcinomas relies on histopathological data such as tumor type, grade, stage, and lymphovascular invasion. We herein present the recent advances in the pathological appreciation of these criteria, relying in the last 2020 WHO classification of female genital tumours. Furthermore, molecular typing of endometrial carcinoma has become a rule with strong prognostic and therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Endometrial Neoplasms
Share to Immunohistochemistry

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Prognosis

Source

Identifiers

PMID: 34340872
DOI: 10.1016/j.annpat.2021.07.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Endometrial carcinomas in 2021: What to say and what to do?]PMID 34340872Read ↗

Untitled literature recordSemantic proximity Read ↗

New clinicopathological concept of endometrial carcinoma with integration of histological features and molecular profiles.Semantic proximity Read ↗

Mapping evidence and gaps in diagnostic characteristics of endometrial carcinomas of the uterine corpus: implications for the WHO Classification of tumours, research, and clinical practiceSemantic proximity Read ↗

Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging.Semantic proximity Read ↗

FIGO 2023 Staging and Molecular Classification of 172 patients with Endometrial CancerSemantic proximity Read ↗

Integrated clinicopathologic and molecular analysis of endometrial carcinoma: Prognostic impact of the new ESGO-ESTRO-ESP endometrial cancer risk classification and proposal of histopathologic algorithm for its implementation in clinical practiceSemantic proximity Read ↗

Analysis of Differences in the Classification of Endometrial Cancer Patients in PolandSemantic proximity Read ↗

Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancerSemantic proximity Read ↗

Molecular Characterization and Clinical Implications of Endometrial Cancer.Semantic proximity Read ↗

Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.Semantic proximity Read ↗

The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and futureSemantic proximity Read ↗

Clinical application of FIGO 2023 staging system of endometrial cancer in a Chinese cohortSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.